Instalab

Albumin

24 Hour Urine Test
Catch silent kidney and blood vessel damage years before standard kidney tests show anything is wrong.

Should you take a Albumin test?

This test is most useful if any of these apply to you.

Living With Diabetes
If your blood sugar runs high, this is one of the earliest signs of kidney damage you can catch, often years before standard kidney tests change.
Managing High Blood Pressure
High blood pressure damages the tiny filters in your kidneys, and this test catches that damage before your standard kidney labs do.
Worried About Your Heart
Even small amounts of this protein in your urine signal blood vessel damage throughout your body, including the vessels feeding your heart.
Family History of Kidney Disease
Kidney damage runs in families and is silent for years. A baseline test in your 30s or 40s gives you a number to track before any problem starts.

About Albumin

If you want to see kidney trouble coming, this is one of the earliest warning signs you can measure. Long before your standard blood tests for kidney function start to drift, the filters inside your kidneys can begin leaking small amounts of a blood protein called albumin into your urine. That leak is one of the first detectable signs that something has changed.

It is also one of the most underused predictors of heart disease in healthy adults. The same tiny blood vessel damage that lets albumin slip into your urine is happening throughout your body, including in the vessels that feed your heart and brain. A 24-hour urine albumin test gives you a quiet, early read on both.

What This Test Actually Measures

Your kidneys filter about 180 liters of blood per day. Albumin, the most abundant protein in your bloodstream, is normally too large and too negatively charged to pass through the kidney's filter membrane. When that membrane becomes even slightly damaged, small amounts of albumin start to escape into the urine.

A 24-hour urine collection captures every drop of urine you produce over a full day, then a lab measures the total milligrams of albumin lost during that period. This is considered the reference standard for measuring albuminuria because it averages out the natural ups and downs that happen across the day. A spot urine test gives you a snapshot. A 24-hour collection gives you the full daily total.

Why Even a Small Leak Matters

The thing that makes albumin in urine such a powerful marker is that the risk does not start at the official cutoff. It rises smoothly across the entire range, including levels that most labs would label as normal. In a community-based study of over 8,000 adults, every doubling of urinary albumin excretion was associated with about a 36% higher risk of a cardiovascular event.

In a separate analysis of more than 37,000 working adults, even values below the standard 30 mg cutoff predicted future high blood pressure and cardiovascular death. The bottom line: there is no truly safe level. Lower is better, and any rise above your personal baseline is worth paying attention to.

Heart Disease and Mortality

Urinary albumin is one of the strongest available predictors of dying from cardiovascular disease, and it works in people with and without diabetes. In the PREVEND study, a Dutch general-population cohort, higher urinary albumin concentrations were linked to higher all-cause mortality and an even sharper rise in death from cardiovascular causes, after adjusting for traditional risk factors like blood pressure, cholesterol, and smoking.

A separate review in the cardiology literature found that adults with any detectable albuminuria carried roughly 40% higher risk of clinical coronary artery disease. In people with type 2 diabetes from the SAVOR-TIMI 53 trial, even mildly elevated levels (10 to 29 mg per gram of creatinine) were tied to a 65% higher risk of cardiovascular death. Heavy albuminuria more than doubled that risk.

The reason this marker tracks heart risk so closely is mechanical. The same dysfunction in the lining of small blood vessels that lets albumin leak through the kidneys is also damaging the vessels in your heart, brain, and elsewhere. Albumin in urine is essentially a window into the health of your entire vascular system.

Diabetes and Kidney Disease Progression

If you have diabetes, this test is one of the most important numbers you can track. Albuminuria typically appears years before any drop in standard kidney function tests, and it predicts whether you are heading toward diabetic kidney disease. Roughly 30 to 40% of people with diabetes eventually develop kidney damage, and the rising albumin loss is usually the first quantifiable sign.

In type 1 diabetes, the landmark DCCT trial showed that tight blood sugar control reduced the rate of new microalbuminuria by 39% and reduced progression to clinical albuminuria by 54%. In type 2 diabetes, the UKPDS trial found that lowering hemoglobin A1c by about 0.9 percentage points cut albumin excretion by 33% over 12 years. These are real biological changes, not lab artifacts.

Heart Failure and Stroke

Albuminuria predicts not just coronary disease but also heart failure and stroke. In the CHARM trial, people with heart failure who had moderately or severely elevated albuminuria had a 60 to 80% higher risk of death and a 30 to 70% higher risk of heart failure hospitalization, even after accounting for kidney function. In the SOLVD trial, dipstick-detected protein in urine independently predicted an 81% higher risk of heart failure hospitalization.

There is also a notable connection to clot risk. In the PREVEND cohort, people with microalbuminuria (30 to 300 mg per 24 hours) had double the risk of venous blood clots, independent of standard risk factors. The picture that emerges is consistent: small amounts of albumin in urine are a marker of widespread vascular dysfunction, not just a kidney issue.

Reference Ranges

Before reading these ranges, know that day-to-day variation in albumin excretion is high enough that a single result should always be confirmed with a repeat test. The KDIGO international guidelines define chronic kidney disease starting at 30 mg per 24 hours, but cardiovascular risk begins to climb well below that threshold.

Tier24-Hour Albumin ExcretionWhat It Suggests
OptimalLess than 10 mg per 24 hoursLowest cardiovascular and kidney risk based on population data.
Normal (A1)Less than 30 mg per 24 hoursWithin standard reference range, but risk still rises gradually as you approach 30.
Moderately Increased (A2)30 to 300 mg per 24 hoursPreviously called microalbuminuria. Marks early kidney damage and elevated cardiovascular risk.
Severely Increased (A3)Greater than 300 mg per 24 hoursPreviously called macroalbuminuria. Indicates established kidney disease and high risk of progression.

These tiers are drawn from KDIGO guidelines and published research. Your lab may use slightly different cutpoints or assay methods. Compare your results within the same lab over time for the most meaningful trend.

Tracking Your Trend

A single 24-hour urine albumin reading tells you something. A series of them tells you much more. Albumin excretion has high day-to-day variability in healthy adults, which is exactly why guidelines require two out of three abnormal results before diagnosing persistent albuminuria. Treat your first test as a baseline, not a verdict.

If you have diabetes, high blood pressure, or any cardiovascular risk factor, you should know this number by your 30s and recheck it at least annually. If you are starting a new medication or making serious lifestyle changes that target blood pressure, blood sugar, or weight, retest in 3 to 6 months to see whether the changes are working. If your first result is in the moderately increased range, repeat the test within a few months to confirm before drawing any conclusions.

The trajectory matters more than any single number. A baseline of 12 mg climbing to 25 mg over two years tells a very different story than a stable reading of 25 mg. Track the direction.

When Results Can Be Misleading

Several common situations can temporarily push your albumin excretion higher without indicating real kidney damage. Knowing them helps you avoid acting on a falsely alarming reading.

  • Recent intense exercise: vigorous activity in the hours before collection can transiently raise urinary albumin. Avoid heavy workouts for 24 hours before starting your collection.
  • Urinary tract infection or visible blood in urine: both can dramatically increase albumin readings. Wait until any infection is treated and resolved, and avoid testing during menstruation.
  • Acute illness, fever, or severe stress: temporary spikes can occur during any acute physical stress. Retest at least 2 weeks after recovery.
  • Incomplete 24-hour collection: missing even a single urination throws off the entire total. The collection error rate is the single biggest reason 24-hour samples produce misleading results.

A few medications can also nudge the number without reflecting kidney damage. NSAIDs like ibuprofen can transiently affect kidney filtration and albumin handling. ACE inhibitors and ARBs lower albuminuria as part of their therapeutic effect, so a low reading on these drugs reflects treatment response, not necessarily a return to normal kidney biology.

What Moves This Biomarker

Evidence-backed interventions that affect your Albumin level

Decrease
Take an ACE inhibitor or angiotensin receptor blocker (ARB)
These blood pressure medications reduce urinary albumin excretion and slow the progression of kidney disease, even in people without high blood pressure. In landmark trials in diabetic kidney disease, they reduced albuminuria substantially and lowered the risk of progression to kidney failure. They are the first-line treatment whenever albuminuria is detected.
MedicationStrong Evidence
Decrease
Take an SGLT2 inhibitor (such as dapagliflozin, empagliflozin, or canagliflozin)
In a meta-analysis of 8 randomized trials enrolling 5,512 people with type 2 diabetes and albuminuria, SGLT2 inhibitors added on top of ACE inhibitors or ARBs significantly reduced albuminuria compared with standard care alone. A 30% reduction in albuminuria has been linked to about a 20% lower risk of end-stage kidney disease. These drugs also benefit people with chronic kidney disease without diabetes.
MedicationStrong Evidence
Decrease
Take a non-steroidal mineralocorticoid receptor antagonist (finerenone)
In the FIDELIO-DKD trial in people with type 2 diabetes and chronic kidney disease, finerenone produced about a 40% reduction in urine albumin-to-creatinine ratio that persisted over time, on top of standard ACE inhibitor or ARB therapy. It also slowed loss of kidney filtration function over years of follow-up.
MedicationStrong Evidence
Decrease
Achieve intensive blood sugar control if you have diabetes
In type 1 diabetes, the DCCT trial showed that tight glucose control reduced new microalbuminuria by 39% and reduced progression to clinical albuminuria by 54%. In type 2 diabetes, the UKPDS trial found that lowering hemoglobin A1c by about 0.9 percentage points reduced albumin excretion by 33% over 12 years. The benefit persists for decades after the period of tight control.
MedicationStrong Evidence
Decrease
Achieve and maintain blood pressure below 130/80
Lowering systolic blood pressure reduces the mechanical pressure driving albumin through the kidney filter. Multiple trials in diabetic and non-diabetic kidney disease show that tighter blood pressure control reduces albuminuria and slows progression of kidney damage. Guidelines recommend a target below 130/80 once albuminuria is detected.
LifestyleStrong Evidence
Increase
Smoke cigarettes
Smoking damages the lining of small blood vessels throughout the body, including the kidney filters, and is consistently associated with higher urinary albumin excretion in population studies. Smokers also have faster progression of any existing albuminuria. The damage reflects real vascular dysfunction, not a measurement artifact.
LifestyleModerate Evidence

Frequently Asked Questions

References

13 studies
  1. Hillege HL, Fidler V, Diercks GF, Van Gilst WH, De Zeeuw D, Van Veldhuisen DJ, Gans RO, Janssen WM, Grobbee DE, De Jong PECirculation2002
  2. Brantsma AH, Bakker SJ, Hillege HL, De Zeeuw D, De Jong PE, Gansevoort RTJournal of the American Society of Nephrology2008
  3. Sung KC, Ryu S, Lee JY, Lee SH, Cheong E, Hyun YY, Lee KB, Kim H, Byrne CDJournal of the American Heart Association2016
  4. Currie G, Delles CJournal of the American Heart Association2023
  5. Khan MS, Shahid I, Anker SD, Fonarow GC, Fudim M, Hall ME, Hernandez a, Morris AA, Shafi T, Weir MR, Zannad F, Bakris GL, Butler JJournal of the American College of Cardiology2023